The United States of America As Represented by the Department of Health

National Institutes of Health, a Component of the US Dept. of Health & Human Services

The United States of America As Represented by the Secretary of

Donald G Blair

Stephen D Showalter

Esther Priel

Robert J Fisher

Meropi A Athanasiou

George J Mavrothalassitis

Gregory J Beal, Jr

Dionyssios N Sgouras

George F Vande Woude

Marianne K Oskarsson

William L McClements

The present invention relates, inter alia, to the ERF gene and to the products encoded by this gene. More particularly, the present invention relates to DNA sequences encoding ERF and AERF; polypeptides encoded by such DNA sequences; ERF chimeric molecules; and methods of using ERF and ERF chimeric molecules to reduce tumorigenicity in a tumor cell.

ETS2 repressor factor (ERF)

ETS2 repressor factor (ERF) genetic locus and its products

The present invention is directed to the use of pharmaceutical compositions, containing an effective amount of topoisomerase I inhibitor such as camptothecin, useful in blocking both the initiation of infection and replication of retroviruses in host cells, thus reducing and eliminating retroviral production in infected cells. Use of such inhibitors provides as means of reducing or eliminating retroviral infections and their deleterious consequences in infected humans and animals.

Method of treating retroviral infections in mammals

The production of vectors composed of portions of retrovirus, particularly of Moloney sarcoma virus DNA including the 'LTR' sequence which can activate genes and additional viral sequences which can 'rescue' these genes into a replicating virus particle.

LTR-Vectors

Growing community of inventors

Kensington, MD, United States of America

Donald G Blair